{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:48:36Z","timestamp":1792090116637,"version":"4.4.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fresenius Kabi SwissBioSim GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive chemotherapy. This review provides an up-to-date assessment of the patient and cost burden of chemotherapy-induced neutropenia\/FN in the US, and summarizes recommendations for FN prophylaxis, including the interim guidance that was recommended during the coronavirus disease 2019 (COVID-19) pandemic. This review indicates that neutropenia\/FN place a significant burden on patients in terms of hospitalizations and mortality. Most patients with neutropenia\/FN presenting to the emergency department will be hospitalized, with an average length of stay of 6, 8, and 10 days for elderly, pediatric, and adult patients, respectively. Reported in-hospital mortality rates for neutropenia\/FN range from 0.4% to 3.0% for pediatric patients with cancer, 2.6% to 7.0% for adults with solid tumors, and 7.4% for adults with hematologic malignancies. Neutropenia\/FN also place a significant cost burden on US healthcare systems, with average costs per neutropenia\/FN hospitalization estimated to be up to $40 000 for adult patients and $65 000 for pediatric patients. Evidence-based guidelines recommend prophylactic granulocyte colony-stimulating factors (G-CSFs), which have been shown to reduce FN incidence while improving chemotherapy dose delivery. Availability of biosimilars may improve costs of care. Efforts to decrease hospitalizations by optimizing outpatient care could reduce the burden of neutropenia\/FN; this was particularly pertinent during the COVID-19 pandemic since avoidance of hospitalization was needed to reduce exposure to the virus, and resulted in the adaptation of recommendations to prevent FN, which expanded the indications for G-CSF and\/or lowered the threshold of use to &amp;gt;10% risk of FN.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac074","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:21:15Z","timestamp":1648639275000},"page":"625-636","source":"Crossref","is-referenced-by-count":145,"title":["Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?"],"prefix":"10.1093","volume":"27","author":[{"given":"Ralph","family":"Boccia","sequence":"first","affiliation":[{"name":"Center for Cancer and Blood Disorders , Bethesda, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glaspy","sequence":"additional","affiliation":[{"name":"UCLA School of Medicine , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[{"name":"Cancer Centre, Clinique de Genolier , Genolier , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2022081221234424700_CIT0001","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"2022081221234424700_CIT0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JOP.2014.001492","article-title":"Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors.","volume":"11","author":"Weycker","year":"2015","journal-title":"J Oncol Pract"},{"key":"2022081221234424700_CIT0003","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cam4.200","article-title":"Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.","volume":"3","author":"Culakova","year":"2014","journal-title":"Cancer Med"},{"key":"2022081221234424700_CIT0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","article-title":"Evaluation and management of patients with isolated neutropenia.","volume":"50","author":"Newburger","year":"2013","journal-title":"Semin Hematol"},{"key":"2022081221234424700_CIT0005","author":"BMJ Best Medical Practice.","year":"22, 2021"},{"key":"2022081221234424700_CIT0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0007","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022081221234424700_CIT0008","author":"National Comprehensive Cancer Network.","year":"20, 2021"},{"key":"2022081221234424700_CIT0009","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archinte.1992.00400190095018","article-title":"Descriptive epidemiology of agranulocytosis.","volume":"152","author":"Strom","year":"1992","journal-title":"Arch Intern Med"},{"key":"2022081221234424700_CIT0010","first-page":"00165","article-title":"Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management.","volume":"5","author":"Rasmy","year":"2016","journal-title":"J Cancer Prev Curr Res"},{"key":"2022081221234424700_CIT0011","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs.","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"2022081221234424700_CIT0012","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archinte.159.4.369","article-title":"A population-based case-cohort study of drug-associated agranulocytosis.","volume":"159","author":"van der Klauw","year":"1999","journal-title":"Arch Intern Med"},{"key":"2022081221234424700_CIT0013","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.10295","article-title":"Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.","volume":"72","author":"van Staa","year":"2003","journal-title":"Am J Hematol"},{"key":"2022081221234424700_CIT0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/B:EJEP.0000032371.97823.85","article-title":"Incidence of agranulocytosis in southwest France.","volume":"19","author":"Th\u00e9ophile","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"2022081221234424700_CIT0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population-based drug-induced agranulocytosis.","volume":"165","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"Arch Intern Med"},{"key":"2022081221234424700_CIT0016","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update.","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"2022081221234424700_CIT0018","first-page":"19","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours.","volume":"17","author":"Khan","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2022081221234424700_CIT0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6955-4-4","article-title":"Experiencing neutropenia: quality of life interviews with adult cancer patients.","volume":"4","author":"Fortner","year":"2005","journal-title":"BMC Nurs"},{"key":"2022081221234424700_CIT0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00520-014-2553-0","article-title":"Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.","volume":"23","author":"Pathak","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022081221234424700_CIT0021","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/annonc\/mdj092","article-title":"Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis.","volume":"17","author":"Lalami","year":"2006","journal-title":"Ann Oncol"},{"key":"2022081221234424700_CIT0022","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer.","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"2022081221234424700_CIT0023","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"2022081221234424700_CIT0024","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"2022081221234424700_CIT0025","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1634\/theoncologist.12-4-478","article-title":"Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.","volume":"12","author":"Bennett","year":"2007","journal-title":"Oncologist"},{"key":"2022081221234424700_CIT0026","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.","volume":"16","author":"Dulisse","year":"2013","journal-title":"J Med Econ"},{"key":"2022081221234424700_CIT0027","author":"American Society of Clinical Oncology"},{"key":"2022081221234424700_CIT0028","author":"European Society for Medical Oncology","year":"2021"},{"key":"2022081221234424700_CIT0029","first-page":"1-4","article-title":"Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic.","author":"Griffiths","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2022081221234424700_CIT0030","doi-asserted-by":"crossref","first-page":"e0216835","DOI":"10.1371\/journal.pone.0216835","article-title":"Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.","volume":"14","author":"Baugh","year":"2019","journal-title":"PLoS One"},{"key":"2022081221234424700_CIT0031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpeds.2018.06.056","article-title":"National trends in hospitalization for fever and neutropenia in children with cancer, 2007-2014.","volume":"202","author":"Lekshminarayanan","year":"2018","journal-title":"J Pediatr"},{"key":"2022081221234424700_CIT0032","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012.","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"2022081221234424700_CIT0033","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPH.0000000000000716","article-title":"Pediatric oncology discharges with febrile neutropenia: variation in location of care.","volume":"39","author":"Alvarez","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022081221234424700_CIT0034","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/08880018.2015.1102998","article-title":"Fever and neutropenia hospital discharges in children with cancer: a 2012 update.","volume":"33","author":"Mueller","year":"2016","journal-title":"Pediatr Hematol Oncol"},{"key":"2022081221234424700_CIT0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12885-015-1413-8","article-title":"Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009.","volume":"15","author":"Mueller","year":"2015","journal-title":"BMC Cancer"},{"key":"2022081221234424700_CIT0036","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/pbc.25288","article-title":"Why pediatric patients with cancer visit the emergency department: United States, 2006\u20132010.","volume":"62","author":"Mueller","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2022081221234424700_CIT0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00520-019-04795-0","article-title":"Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"2022081221234424700_CIT0038","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med"},{"key":"2022081221234424700_CIT0039","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.24465","article-title":"Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.","volume":"91","author":"Xiao","year":"2016","journal-title":"Am J Hematol"},{"key":"2022081221234424700_CIT0040","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update.","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0041","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00277-017-3217-1","article-title":"Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.","volume":"97","author":"Scappaticci","year":"2018","journal-title":"Ann Hematol"},{"key":"2022081221234424700_CIT0042","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.cllc.2017.10.013","article-title":"Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia.","volume":"19","author":"Cupp","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2022081221234424700_CIT0043","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1078155216687150","article-title":"Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.","volume":"23","author":"Butts","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2022081221234424700_CIT0044","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","article-title":"Advances in the treatment of neutropenia.","volume":"3","author":"Dale","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"2022081221234424700_CIT0045","first-page":"765","article-title":"Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia.","volume":"41","author":"Moore","year":"2016","journal-title":"P T"},{"key":"2022081221234424700_CIT0046","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update.","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0047","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0048","author":"European Medicines Agency.","year":"13, 2020"},{"key":"2022081221234424700_CIT0049","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2146\/ajhp140194","article-title":"Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.","volume":"72","author":"Pherwani","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"2022081221234424700_CIT0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1188\/14.CJON.426-431","article-title":"Preventing infections during cancer treatment: development of an interactive patient education website.","volume":"18","author":"Dunbar","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"2022081221234424700_CIT0051","first-page":"103","article-title":"Role of nurses in the assessment and management of chemotherapy-related side effects in cancer patients.","volume":"4","author":"Roe","year":"2014","journal-title":"Nursing: Research and Reviews"},{"key":"2022081221234424700_CIT0052","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.annemergmed.2016.01.021","article-title":"The emergency care of patients with cancer: setting the research agenda.","volume":"68","author":"Brown","year":"2016","journal-title":"Ann Emerg Med"},{"key":"2022081221234424700_CIT0053","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00520-014-2377-y","article-title":"Improving hospital performance in the treatment of febrile neutropenia.","volume":"23","author":"Meisenberg","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022081221234424700_CIT0054","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","article-title":"The multinational association for supportive care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.","volume":"21","author":"Klastersky","year":"2013","journal-title":"Support Care Cancer"},{"key":"2022081221234424700_CIT0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bjc.2011.284","article-title":"Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.","volume":"105","author":"Carmona-Bayonas","year":"2011","journal-title":"Br J Cancer"},{"key":"2022081221234424700_CIT0056","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","article-title":"Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE Study.","volume":"33","author":"Carmona-Bayonas","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022081221234424700_CIT0057","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.annemergmed.2016.11.007","article-title":"Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department.","volume":"69","author":"Coyne","year":"2017","journal-title":"Ann Emerg Med"},{"key":"2022081221234424700_CIT0058","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40259-020-00411-4","article-title":"Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure.","volume":"34","author":"Cornes","year":"2020","journal-title":"BioDrugs"},{"key":"2022081221234424700_CIT0059","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors.","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv Ther"},{"key":"2022081221234424700_CIT0060","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.2147\/CMAR.S164201","article-title":"The role of biosimilars in value-based oncology care.","volume":"10","author":"Patel","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2022081221234424700_CIT0061","author":"European Medicines Agency","year":"2, 2019"},{"key":"2022081221234424700_CIT0062","first-page":"94","article-title":"Patient-administered biologic and biosimilar filgrastim may offer more affordable options for patients with nonmyeloid malignancies receiving chemotherapy in the United States: a budget impact analysis from the payer perspective.","volume":"25","author":"Trautman","year":"2019","journal-title":"J Manag Care Spec Pharm"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/625\/45407921\/oyac074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/625\/45407921\/oyac074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T21:25:00Z","timestamp":1660339500000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/8\/625\/6584944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac074","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,12]]}}}